(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 March 2011 (03.03.2011)

PCT

(10) International Publication Number
WO 2011/025964 A2

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2010/047006

(22) International Filing Date:
27 August 2010 (27.08.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/238,152 29 August 2009 (29.08.2009) US
61/261,728 16 November 2009 (16.11.2009) US

(71) Applicant *(for all designated States except US)*: **ABBOTT LABORATORIES** [US/US]; 100 Abbott Park Road, Abbott Park, IL 60064 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BENATUIL, Lorenzo** [VE/US]; 33 Mohawk Drive, Northborough, MA 01532 (US). **BOGHAERT, Erwin, R.** [BE/US]; 4510 Springbrook Road, Pleasant Prairie, WI 53158 (US). **GU, Jijie** [US/US]; 19 Crimson Drive, Shrewsbury, MA 01545 (US). **HARRIS, Maria** [IT/US]; 55 Trowbridge Lane, Shrewsbury, MA 01545 (US). **HICKSON, Jonathan, A.** [US/US]; 725 Northwind Lane, Lake Villa, IL 60046 (US). **HSIEH, Chung-Ming** [US/US]; 22 Olde Field Road, Newton, MA 02459 (US). **KUTSKOVA, Yuliya** [RU/US]; 183 Whitney Street, Northborough, MA 01532 (US). **LI, Yingchun** [CN/US]; 103 Newfield Drive, Buffalo Grove, IL 60089 (US). **LIU, Zhihong** [CN/US]; 1455 Greystone Avenue, Gurnee, IL 60031 (US). **MORGAN-LAPPE, Susan** [US/US]; 5419 North Canfield Avenue, Chicago, IL 60656 (US).

(74) Agents: **REININGER, Irene, M.** et al.; Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/025964 A2

(54) **Title**: THERAPEUTIC DLL4 BINDING PROTEINS

(57) **Abstract**: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.